Fig. 1From: Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiationChanges in disease activity after 6 months. a Changes in BVAS after 6 months of induction therapy by treatment group. Data are mean ± SD of BVAS in each treatment group. *p < 0.01 according to paired Student’s t test. b Rate of remission in BVAS by treatment group. Statistical differences were determined by Fisher’s exact testBack to article page